Amyotrophic lateral sclerosis
RH Brown, A Al-Chalabi - New England Journal of Medicine, 2017 - Mass Medical Soc
Amyotrophic Lateral Sclerosis | New England Journal of Medicine Skip to main content The
New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …
New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …
Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature
Background: Amyotrophic lateral sclerosis (ALS) is relatively rare, yet the economic and
social burden is substantial. Having accurate incidence and prevalence estimates would …
social burden is substantial. Having accurate incidence and prevalence estimates would …
Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial
Objective: To assess masitinib in the treatment of ALS. Methods: Double-blind study,
randomly assigning 394 patients (1: 1: 1) to receive riluzole (100 mg/d) plus placebo or …
randomly assigning 394 patients (1: 1: 1) to receive riluzole (100 mg/d) plus placebo or …
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease, is characterized
by the degeneration of both upper and lower motor neurons, which leads to muscle …
by the degeneration of both upper and lower motor neurons, which leads to muscle …
Clinical diagnosis and management of amyotrophic lateral sclerosis
O Hardiman, LH Van Den Berg… - Nature reviews neurology, 2011 - nature.com
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that results in
progressive loss of bulbar and limb function. Patients typically die from respiratory failure …
progressive loss of bulbar and limb function. Patients typically die from respiratory failure …
Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis
JA Andrews, CE Jackson… - … Lateral Sclerosis and …, 2020 - Taylor & Francis
Objective To compare the effect of riluzole on median survival in population studies of
patients with amyotrophic lateral sclerosis (ALS) with that observed in clinical trials …
patients with amyotrophic lateral sclerosis (ALS) with that observed in clinical trials …
Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?
H Mitsumoto, BR Brooks, V Silani - The Lancet Neurology, 2014 - thelancet.com
Amyotrophic lateral sclerosis (ALS) is one of the most rapidly progressive
neurodegenerative diseases of unknown cause. Riluzole is the only drug that slows disease …
neurodegenerative diseases of unknown cause. Riluzole is the only drug that slows disease …
[HTML][HTML] ALS pathogenesis and therapeutic approaches: the role of mesenchymal stem cells and extracellular vesicles
R Bonafede, R Mariotti - Frontiers in cellular neuroscience, 2017 - frontiersin.org
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by
progressive muscle paralysis determined by the degeneration of motoneurons in the motor …
progressive muscle paralysis determined by the degeneration of motoneurons in the motor …
Cognitive changes predict functional decline in ALS: a population-based longitudinal study
Objective: To determine whether cognitive status in patients with amyotrophic lateral
sclerosis (ALS) is a useful predictor of attrition and motor and cognitive decline. Methods …
sclerosis (ALS) is a useful predictor of attrition and motor and cognitive decline. Methods …
Disease-modifying therapies in amyotrophic lateral sclerosis
A Chiò, L Mazzini, G Mora - Neuropharmacology, 2020 - Elsevier
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of adult life, causing
weakness and wasting of voluntary muscles, associated in about 50% of cases with a …
weakness and wasting of voluntary muscles, associated in about 50% of cases with a …